Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENLV Enlivex Therapeutics	$1.03 +14.4%	$0.96	$0.81 ▼ $1.76	$24.36M	0.74	128,475 shs	287,538 shs
IXHL Incannex Healthcare	$0.21 +0.9%	$0.34	$0.08 ▼ $3.55	$6.13M	7.63	13.82 million shs	13.97 million shs
MIRA MIRA Pharmaceuticals	$1.25 +3.3%	$1.16	$0.51 ▼ $5.01	$21.15M	1.96	2.20 million shs	79,092 shs
QTTB Q32 Bio	$1.68 +0.6%	$1.75	$1.38 ▼ $53.79	$20.49M	-0.03	200,104 shs	66,429 shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENLV Enlivex Therapeutics	0.00%	-6.45%	-9.50%	-21.30%	-38.01%
IXHL Incannex Healthcare	0.00%	+15.00%	-20.69%	-72.14%	-93.79%
MIRA MIRA Pharmaceuticals	0.00%	-13.57%	-16.55%	+12.04%	+63.96%
QTTB Q32 Bio	0.00%	-12.11%	-5.65%	-23.74%	-91.03%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ENLV Enlivex Therapeutics	3.4561 of 5 stars	3.7	5.0	2.6	0.8	1.3
IXHL Incannex Healthcare	0.7745 of 5 stars	0.0	4.0	3.1	0.8	0.0
MIRA MIRA Pharmaceuticals	3.327 of 5 stars	3.7	5.0	4.1	0.0	0.6
QTTB Q32 Bio	3.4044 of 5 stars	3.1	4.0	4.1	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENLV Enlivex Therapeutics	3.33	Buy	$10.00	870.87% Upside
IXHL Incannex Healthcare	0.00	N/A	N/A	N/A
MIRA MIRA Pharmaceuticals	3.33	Buy	$14.00	1,020.00% Upside
QTTB Q32 Bio	2.25	Hold	$24.71	1,371.09% Upside

Current Analyst Ratings Breakdown

Latest IXHL, ENLV, QTTB, and MIRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/21/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
4/3/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
3/24/2025	ENLV Enlivex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$6.00 ➝ $7.00

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	$1.62 per share	N/A
IXHL Incannex Healthcare	$98K	62.50	N/A	N/A	$0.05 per share	4.16
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	$0.30 per share	N/A
QTTB Q32 Bio	-$6.65M	-3.08	N/A	N/A	$22.47 per share	0.07

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENLV Enlivex Therapeutics	-$29.07M	-$0.66	N/A	N/A	N/A	N/A	-67.57%	-58.45%	8/29/2025 (Estimated)
IXHL Incannex Healthcare	-$18.46M	-$1.21	N/A	∞	N/A	N/A	-289.30%	-154.96%	N/A
MIRA MIRA Pharmaceuticals	-$11.98M	-$0.51	N/A	N/A	N/A	N/A	-337.44%	-280.58%	8/12/2025 (Estimated)
QTTB Q32 Bio	-$112.96M	-$4.94	N/A	N/A	N/A	N/A	-146.18%	-54.49%	8/6/2025 (Estimated)

Latest IXHL, ENLV, QTTB, and MIRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/30/2025	Q1 2025	ENLV Enlivex Therapeutics	-$0.16	-$0.15	+$0.01	-$0.15	N/A	N/A
5/15/2025	Q3 2025	IXHL Incannex Healthcare	-$0.46	-$0.24	+$0.22	-$0.20	$0.16 million	$0.10 million
5/14/2025	Q1 2025	MIRA MIRA Pharmaceuticals	-$0.15	-$0.11	+$0.04	-$0.11	N/A	N/A
5/8/2025	Q1 2025	QTTB Q32 Bio	-$1.23	-$0.90	+$0.33	-$0.90	N/A	N/A
3/31/2025	Q4 2024	ENLV Enlivex Therapeutics	-$0.16	-$0.23	-$0.07	-$0.23	N/A	N/A
3/28/2025	Q4 2024	MIRA MIRA Pharmaceuticals	-$0.29	-$0.15	+$0.14	-$0.15	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	N/A
IXHL Incannex Healthcare	N/A	N/A	N/A	N/A	N/A
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
QTTB Q32 Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENLV Enlivex Therapeutics	N/A	9.71	9.71
IXHL Incannex Healthcare	2.47	1.80	1.65
MIRA MIRA Pharmaceuticals	N/A	6.11	6.11
QTTB Q32 Bio	0.61	6.53	6.53

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ENLV Enlivex Therapeutics	1.02%
IXHL Incannex Healthcare	0.43%
MIRA MIRA Pharmaceuticals	35.16%
QTTB Q32 Bio	31.32%

Insider Ownership

Company	Insider Ownership
ENLV Enlivex Therapeutics	12.28%
IXHL Incannex Healthcare	15.49%
MIRA MIRA Pharmaceuticals	6.65%
QTTB Q32 Bio	40.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ENLV Enlivex Therapeutics	70	23.65 million	18.78 million	Optionable
IXHL Incannex Healthcare	3	29.43 million	13.12 million	Not Optionable
MIRA MIRA Pharmaceuticals	2	16.92 million	15.46 million	Not Optionable
QTTB Q32 Bio	39	12.20 million	10.22 million	N/A

IXHL, ENLV, QTTB, and MIRA Headlines

Recent News About These Companies

Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025 | prnewswire.com

Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata

April 30, 2025 | prnewswire.com

Leerink Partners Sticks to Its Hold Rating for Q32 Bio (QTTB)

April 18, 2025 | markets.businessinsider.com

Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata

April 16, 2025 | prnewswire.com

All You Need to Know About Q32 Bio (QTTB) Rating Upgrade to Buy

April 8, 2025 | zacks.com

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and Q32 Bio (QTTB)

March 12, 2025 | markets.businessinsider.com

Q32 Bio price target lowered to $15 from $16 at Wells Fargo

March 12, 2025 | markets.businessinsider.com

Q32 Bio Reports Promising Trial Results and Financials

March 12, 2025 | tipranks.com

Q32 Bio: Q4 Earnings Snapshot

March 11, 2025 | sfgate.com

Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update

March 11, 2025 | prnewswire.com

Q32 Bio presents results from SIGNAL-AA Part 2a trial of bempikibart

March 10, 2025 | markets.businessinsider.com

Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting

March 8, 2025 | prnewswire.com

Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting

February 28, 2025 | prnewswire.com

Q32 Bio to Participate in Upcoming March Investor Conferences

February 26, 2025 | prnewswire.com

Piper Sandler Downgrades Q32 Bio (QTTB)

February 12, 2025 | msn.com

BMO Capital Downgrades Q32 Bio (QTTB)

February 12, 2025 | msn.com

Q32 Bio (NASDAQ:QTTB) Stock Quotes, Forecast and News Summary

February 12, 2025 | benzinga.com

Q32 Bio sticks with bempikibart, but loses staff and phase 2 complement inhibitor

February 11, 2025 | fiercebiotech.com

Piper Sandler cuts Q32 Bio stock rating to neutral, slashes target

February 11, 2025 | msn.com

Q32 Bio downgraded to Neutral from Overweight at Piper Sandler

February 11, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IXHL, ENLV, QTTB, and MIRA Company Descriptions

Enlivex Therapeutics NASDAQ:ENLV

$1.03 +0.13 (+14.44%)

Closing price 04:00 PM Eastern

Extended Trading

$1.04 +0.01 (+1.46%)

As of 04:35 PM Eastern

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Incannex Healthcare NASDAQ:IXHL

$0.21 +0.00 (+0.92%)

Closing price 04:00 PM Eastern

Extended Trading

$0.21 0.00 (-0.53%)

As of 04:38 PM Eastern

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.

MIRA Pharmaceuticals NASDAQ:MIRA

$1.25 +0.04 (+3.31%)

Closing price 04:00 PM Eastern

Extended Trading

$1.22 -0.03 (-2.32%)

As of 04:37 PM Eastern

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

Q32 Bio NASDAQ:QTTB

$1.68 +0.01 (+0.60%)

Closing price 04:00 PM Eastern

Extended Trading

$1.68 0.00 (0.00%)

As of 04:04 PM Eastern

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time